The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease

被引:81
|
作者
Zohn, Irene E.
De Domenico, Ivana
Pollock, Andrew
Ward, Diane McVey
Goodman, Jessica F.
Liang, Xiayun
Sanchez, Amaru J.
Niswander, Lee
Kaplan, Jerry [1 ]
机构
[1] Univ Colorado, Sect Dev Biol, Dept Pediat, Howard Hughes Med Inst, Boulder, CO 80309 USA
[2] Hlth Sci Ctr, Aurora, CO USA
[3] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA
[4] Univ Colorado, Hlth Sci Ctr, Dept Pathol, Boulder, CO 80309 USA
关键词
D O I
10.1182/blood-2007-01-066068
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ferroportin disease is caused by mutation of one allele of the iron exporter ferroportin (Fpn/IREG1/SIc40a1/MTP1). All reported human mutations are missense mutations and heterozygous null mutations in mouse Fpn do not recapitulate the human disease. Here we describe the flatiron (ffe) mouse with a missense mutation (H32R) in Fpn that affects its localization and iron export activity. Similar to human patients with classic ferroportin disease, heterozygous ffe/+ mice present with iron loading of Kupffer cells, high serum ferritin, and low transferrin saturation. In macrophages isolated from ffe/+ heterozygous mice and through the use of Fpn plasmids with the ffe mutation, we show that Fpn(ffe) acts as a dominant negative, preventing wild-type Fpn from localizing on the cell surface and transporting iron. These results demonstrate that mutations in Fpn resulting in protein mislocalization act in a dominant-negative fashion to cause disease, and the Fpnffe mouse represents the first mouse model of ferroportin disease.
引用
收藏
页码:4174 / 4180
页数:7
相关论文
共 50 条
  • [1] The flatiron mutation in mouse ferroportin acts as a dominant negative to cause Hemochromatosis Type IV
    De Domenico, I.
    Zohn, I. E.
    Pollock, A.
    Ward, D. M.
    Goodman, J. F.
    Liang, X.
    Sanchez, A. J.
    Niswander, L.
    Kaplan, J.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 529 - 529
  • [2] Flatiron mice and ferroportin disease
    Johnson, Erin E.
    Wessling-Resnick, Marianne
    [J]. NUTRITION REVIEWS, 2007, 65 (07) : 341 - 345
  • [3] The dynamics of hepcidin-ferroportin internalization and consequences of a novel ferroportin disease mutation
    Wallace, Daniel F.
    McDonald, Cameron J.
    Ostini, Lesa
    Iser, David
    Tuckfield, Annabel
    Subramaniam, V. Nathan
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (10) : 1052 - 1061
  • [4] Trace Element Distribution in Flatiron Mice, a Genetic Model of Human Ferroportin Disease
    Seo, Young Ah
    Wessling-Resnick, Marianne
    [J]. FASEB JOURNAL, 2016, 30
  • [5] A novel ferroportin mutation in a Canadian family with autosomal dominant hemochromatosis
    Morris, TJ
    Litvinova, MM
    Ralston, D
    Mattman, A
    Holmes, D
    Lockitch, G
    [J]. BLOOD CELLS MOLECULES AND DISEASES, 2005, 35 (03) : 309 - 314
  • [7] Ferroportin mutation in autosomal dominant hemochromatosis: loss of function, gain in understanding
    Fleming, RE
    Sly, WS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (04): : 521 - 522
  • [8] FERROPORTIN DISEASE-AN IMPORTANT CAUSE OF IRON OVERLOAD
    Mahmood, R.
    Labib, M.
    Fisher, N. C.
    [J]. GUT, 2012, 61 : A411 - A412
  • [9] A disease-causing mutation K240E disrupts ferroportin trafficking by SUMO (ferroportin SUMOylation)
    Bayele, Henry K.
    Srai, Surjit Kaila S.
    [J]. BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2021, 25
  • [10] Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload
    Jouanolle, AM
    Douabin-Gicquel, V
    Halimi, C
    Loréal, O
    Fergelot, P
    Delacour, T
    de Lajarte-Thirouard, AS
    Turlin, B
    Le Gall, JY
    Cadet, E
    Rochette, J
    David, V
    Brissot, P
    [J]. JOURNAL OF HEPATOLOGY, 2003, 39 (02) : 286 - 289